Tag: Jaenisch Lab

Precision gene targeting in stem cells corrects disease-causing mutations

July 14, 2011

Using two distinct methods, Whitehead Institute researchers have successfully and consistently manipulated targeted genes in both human embryonic stem (ES) cells and induced pluripotent stem (iPS) cells (adult cells that have been reprogrammed to an embryonic stem cell-like state).

Whitehead Member Rudolf Jaenisch honored for groundbreaking stem cell research

February 15, 2011

Israel’s Wolf Foundation, whose stated mission is “to promote science and art for the benefit of mankind,” has named Whitehead Institute Founding Member Rudolf Jaenisch a recipient of the prestigious 2011 Wolf Prize in Medicine.

Whitehead Member Rudolf Jaenisch to receive MGH's Warren Triennial Prize

December 16, 2010

Whitehead Institute Founding Member Rudolf Jaenisch has been named a recipient of the 2011 Warren Triennial Prize of Massachusetts General Hospital (MGH). 

Whitehead scientist named one of the world's top young innovators

August 25, 2010

Whitehead Institute postdoctoral fellow Yaqub (Jacob) Hanna has been recognized as a 2010 Young Innovator by MIT's Technology Review magazine.

Human embryonic stem cells and reprogrammed cells virtually identical

August 5, 2010

Human embryonic stem (ES) cells and adult cells reprogrammed to an embryonic stem cell-like state—so-called induced pluripotent stem or iPS cells—exhibit very few differences in their gene expression signatures and are nearly indistinguishable in their chromatin state, according to Whitehead Institute researchers.

Protein that predicts prognosis of leukemia patients may also be a therapeutic target

July 8, 2010

Researchers at Whitehead Institute and Children’s Hospital Boston have identified a protein, called Musashi 2, that is predictive of prognosis in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) patients. High levels of Musashi 2 protein is associated with increased cell proliferation, decreased cell maturation, and multiple cancer-related cellular pathways in human leukemias.

Image of purple intestinal epithelial cells extracted from a teratoma seeded by reprogrammed blood cells.

Reprogrammed human blood cells show promise for disease research

July 1, 2010

Cells from frozen human blood samples can be reprogrammed to an embryonic stem-cell-like state, according to Whitehead Institute researchers. These cells can be multiplied and used to study the genetic and molecular mechanisms of blood disorders and other diseases.

Low oxygen levels prevent X chromosome inactivation in human embryonic stem cells

May 13, 2010

Oxygen levels in the lab can permanently alter human embryonic stem (ES) cells, specifically inducing X chromosome inactivation in female cells, according to Whitehead Institute researchers.

Scientists create human embryonic stem cells with enhanced pluripotency

May 3, 2010

Whitehead Institute researchers have converted established human induced pluripotent stem (iPS) cells and human embryonic stem (ES) cells to a base state of greater pluripotency. 

New model tracks the immune response to a T

April 8, 2010

Using T cells primed for the infectious disease toxoplasmosis, Whitehead Institute researchers have created novel mouse models of the immune system that more accurately reflect how immune cells actually respond to pathogens in their presence.

Whitehead Member Rudolf Jaenisch awarded Ernst Schering Prize

September 22, 2009

Whitehead Member Rudolf Jaenisch received today the 2009 Ernst Schering Prize, one of the most prestigious German awards for scientists.

Technique enables efficient gene targeting in human embryonic stem cells

August 13, 2009

A novel technique allows researchers to efficiently and precisely modify or introduce genes into the genomes of human embryonic stem cells (ESCs) and induced pluripotent stem (iPS) cells, according to Whitehead scientists.

Pages

© Whitehead Institute for Biomedical Research              455 Main Street          Cambridge, MA 02142